Clinical Trials of Monoclonal Antibodies to Prevent COVID-19 Now Enrolling | NIH: National Institute of Allergy and Infectious Diseases

Clinical Trials of Monoclonal Antibodies to Prevent COVID-19 Now Enrolling | NIH: National Institute of Allergy and Infectious Diseases

Clinical Trials of Monoclonal Antibodies to Prevent COVID-19 Now Enrolling

Two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs) can prevent infection by SARS-CoV-2 coronavirus are now enrolling healthy adults at clinical trial sites in the United States. Many of the trial sites and study investigators are part of the COVID-19 Prevention Network (CoVPN), recently established by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH).